Deerfield Management Company, L.P. (Series C) Voyager Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.15 - $10.84 $118,103 - $179,055	16,518 Added 106.66%	32,005 $297,000
Q4 2023 Feb 14, 2024	BUY	$6.28 - $8.81 $97,258 - $136,440	15,487 New	15,487 $130,000
Q1 2019 May 15, 2019	SELL	$8.0 - $19.66 $941,176 - $2.31 Million	-117,647 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$8.37 - $20.59 $984,705 - $2.42 Million	117,647	117,647 $2.42 Million

Others Institutions Holding VYGR

# of Institutions

130

Shares Held

34.7M

Call Options Held

39.7K

Put Options Held

34.6K

Black Rock Inc. New York, NY

5.31M
Shares

$30.7 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.2M
Shares

$30.1 Million
0.5% of portfolio
Eco R1 Capital, LLC San Francisco, CA

3.92M
Shares

$22.6 Million
0.99% of portfolio
Vanguard Group Inc Valley Forge, PA

3.19M
Shares

$18.4 Million
0.0% of portfolio
Farallon Capital Management LLC San Francisco, CA

2.29M
Shares

$13.2 Million
0.07% of portfolio

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $223M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account